Table 1.
Detailed description of the characteristics of included studies.
| Author | Year | Gender Male (%) Female (%) |
Age | Type of Autoimmune Disease | Type of Cancer | Immunotherapy Regimen |
|---|---|---|---|---|---|---|
| Bottoni et al.32 | 2014 | 48 (24.1%) 151 (75.9%) |
<60 56.3% ≥60 43.7% |
Autoimmune thyroiditis 55.1% Rheumatoid arthritis12.2% Others32.7% |
Melanoma | CTLA-4 |
| Danlos et al.25 | 2017 | 215 (54.2%) 182 (45.8%) |
62.3 (23–88) | Psoriasis Autoimmune thyroiditis Sjogren’s syndrome Rheumatoid arthritis Other |
Melanoma NSCLC Others |
anti-PD-1 (Pembrolizumab) (Nivolumab) (Avelumab) |
| Schadendorf et al.26 | 2019 | 557(55.3%) 451(44.7%) |
62(18–89) | Endocrine 56.0% Skin 28.0% Gastrointestinal 8.0% Hepatic 4% |
Melanoma | anti-PD-1 (Nivolumab) CTLA-4+anti-PD-1 (Ipilimumab+ Nivolumab) |
| aGulati et al.34 | 2021 | 295 (61.1%) 188 (38.9%) |
Mean 63.29 | Asthma Inflammatory bowel disease Psoriasis Rheumatoid arthritis Eczema Polymyalgia rheumatic Other |
Melanoma | CTLA-4 CTLA-4+anti-PD-1 PD-1 |
| Van der Kooij et al.27 | 2021 | 2538 (58.1%) 1829 (41.9%) |
<65 67.8% ≥65 32.2% |
Rheumatologic AID Endocrine AID Inflammatory bowel disease Other |
Melanoma | CTLA-4 (Ipilimumab) anti-PD-1 (Pembrolizumab) (Nivolumab) CTLA-4+anti-PD-1 |
| Kanai et al.24 | 2018 | 154 (71.3%) 62 (28.7%) |
69 (30–89) | Interstitial lung disease | NSCLC | anti-PD-1 (Nivolumab) |
| Cortellini et al.22 | 2019 | 499 (66.4%) 252 (33.6%) |
69 (24–92) | Thyroid disorders60% Dermatologic16.4% Rheumatologic11.8% Others 11.8% |
NSCLC65.5% Melanoma21.2% Kidney cancer 12.5% Others0.8% |
anti-PD-1 (Pembrolizumab) (Nivolumab) |
| Shibaki et al.20 | 2019 | 223 (62.3%) 135 (37.7%) |
62 (27–84) | Interstitial lung disease | NSCLC | anti-PD-1 (Nivolumab) (Pembrolizumab) |
| Byeon et al.28 | 2020 | 167 (70.5%) 70 (29.5%) |
60 (35–80) | Rheumatoid arthritis7.1% Behcet’s disease7.1% Interstitial lung disease85.3% |
NSCLC | anti-PD-1 (Pembrolizumab) (Nivolumab) |
| Tasaka et al.21 | 2020 | 337 (73.1%) 124 (26.9%) |
69 (34–88) | Interstitial lung disease | NSCLC | anti-PD-L1 (Atezolizumab) |
| Faehling et al.33 | 2020 | 82 (65.1%) 44 (34.9%) |
62.4 (33.5–81.6) | NA | NSCLC | anti-PD-L1 (Durvalumab) |
| Ansel et al.29 | 2020 | 41 (50%) 41 (50%) |
65 (60.6–73.2) | Rheumatoid Arthritis Psoriasis Idiopathic pulmonary fibrosis Raynaud’s Disease Fibromyalgia Post-polio Syndrome Multiple sclerosis |
NSCLC | ati-PD-1 (Pembrolizumab) |
| Han et al.35 | 2022 | 991 (54.4%) 838 (45.6%) |
66.43 (57.5–74) 63.54 (54.4–71) |
Psoriasis Rheumatoid arthritis |
NSCLC Melanoma Kidney Other |
anti-PD-L anti-PD-L1 |
| aLoriot et al.23 | 2020 | 772 (77.4%) 225 (22.6%) |
69 (41–82) 68 (34–93) |
Psoriasis | Urinary tract carcinoma | anti-PD-L1 (Atezolizumab) |
aWe chose baseline characteristics of cohort studies; NSCLC: non-small cell lung cancer; PD-1: programmed cell death protein 1; PD-L1: programmed cell death protein ligand 1; CTLA-4: cytotoxic T-lymphocyte – associated protein 4; NA: not available.